High-Grade Glioma - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 253 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
High-Grade Glioma - Overview
High-Grade Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
High-Grade Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
High-Grade Glioma - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
AngioChem Inc
Arog Pharmaceuticals Inc
Astellas Pharma Inc
Athenex Inc
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
BTG Plc
Cavion LLC
CBT Pharmaceuticals Inc
Concordia International Corp
DelMar Pharmaceuticals Inc
Ipsen SA
Millennium Pharmaceuticals Inc
Nektar Therapeutics
Novartis AG
Ono Pharmaceutical Co Ltd
Sanofi
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Targepeutics Inc
Tocagen Inc
ZIOPHARM Oncology Inc
High-Grade Glioma - Drug Profiles
AdRTSIL-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bendamustine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Gliomas - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for High-Grade Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dabrafenib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dianhydrogalactitol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-7888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etirinotecan pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine + TBio-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GB-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSV-1716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride + TBio-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mibefradil dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
R&D Progress
Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel trevatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
porfimer sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RRX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
High-Grade Glioma - Dormant Projects
High-Grade Glioma - Discontinued Products
High-Grade Glioma - Product Development Milestones
Featured News & Press Releases
May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting
Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings
Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy
Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings
May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings
May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting
Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences
Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for High-Grade Glioma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1 2017
High-Grade Glioma - Pipeline by AngioChem Inc, H1 2017
High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017
High-Grade Glioma - Pipeline by Astellas Pharma Inc, H1 2017
High-Grade Glioma - Pipeline by Athenex Inc, H1 2017
High-Grade Glioma - Pipeline by Bayer AG, H1 2017
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
High-Grade Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
High-Grade Glioma - Pipeline by BTG Plc, H1 2017
High-Grade Glioma - Pipeline by Cavion LLC, H1 2017
High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
High-Grade Glioma - Pipeline by Concordia International Corp, H1 2017
High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
High-Grade Glioma - Pipeline by Ipsen SA, H1 2017
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
High-Grade Glioma - Pipeline by Nektar Therapeutics, H1 2017
High-Grade Glioma - Pipeline by Novartis AG, H1 2017
High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
High-Grade Glioma - Pipeline by Sanofi, H1 2017
High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1 2017
High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
High-Grade Glioma - Pipeline by Targepeutics Inc, H1 2017
High-Grade Glioma - Pipeline by Tocagen Inc, H1 2017
High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
High-Grade Glioma - Dormant Projects, H1 2017
High-Grade Glioma - Discontinued Products, H1 2017